Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionSignet Financial Management, Llc
Latest Disclosed Ownership3,895 shares
Latest Disclosed Value $ 3,009,256
Signet Financial Management, Llc ownership in REGN / Regeneron Pharmaceuticals, Inc.

On May 5, 2026 - Signet Financial Management, Llc filed a 13F-HR form disclosing ownership of 3,895 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $3,009,256 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 8, 2026 disclosing 3,972 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -1.94% during the quarter.

Signet Financial Management, Llc has a history of taking positions in derivatives of the underlying security (REGN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MX:REGN / Regeneron Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,895 -77 -1.94 3,009 -1.83 0.3374
2026-01-08 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,972 -23 -0.58 3,066 36.46 0.3426
2025-11-07 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,995 12 0.30 2,246 7.46 0.2608
2025-07-15 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,983 -20 -0.50 2,091 -17.68 0.2626
2025-04-15 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,003 83 2.12 2,539 -9.06 0.3425
2025-01-13 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,920 -110 -2.73 2,793 -34.09 0.3564
2024-10-23 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,030 5 0.12 4,237 0.14 0.5400
2024-08-02 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,025 5 0.12 4,231 9.33 0.5707
2024-04-15 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,020 78 1.98 3,870 11.76 0.5317
2024-01-30 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,942 -1 -0.03 3,463 6.69 0.5184
2023-10-25 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,943 -46 -1.15 3,245 13.22 0.5359
2023-07-18 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,989 24 0.61 2,866 -12.03 0.4533
2023-04-17 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,965 11 0.28 3,258 14.20 0.5486
2023-02-14 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,954 -33 -0.83 2,853 3.86 0.5095
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,987 20 0.50 2,747 17.14 0.5376
2022-08-15 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,967 0 0.00 2,345 -15.37 0.4465
2022-05-13 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,967 51 1.30 2,771 12.05 0.4635
2022-02-11 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,916 42 1.08 2,473 5.46 0.3745
2021-11-15 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,874 11 0.28 2,345 8.67 0.4048
2021-08-09 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 3,863 -4 -0.10 2,158 17.92 0.7394
2021-05-05 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,867 -129 -3.23 1,830 -5.23 0.3430
2021-02-10 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 3,996 -107 -2.61 1,931 -19.84 0.3904
2020-11-05 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,103 -200 -4.65 2,409 -7.95 0.5327
2020-08-18 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 4,303 -495 -10.32 2,617 -2.17 0.5823
2020-05-20 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 4,798 -605 -11.20 2,675 31.84 0.6302
2020-01-23 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 5,403 -113 -2.05 2,029 6.85 0.3787
2019-11-14 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 5,516 -355 -6.05 1,899 4.63 0.3717
2019-08-13 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 5,871 -785 -11.79 1,815 -18.68 0.3598
2019-05-15 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,656 -248 -3.59 2,232 -13.45 0.4369
2019-02-14 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 6,904 6,475 1,509.32 2,579 1,390.75 0.5620
2018-11-14 2018-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 429 28 6.98 173 25.36 0.0302
2018-08-10 2018-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 401 401 138 0.0243
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-05-15 2019-03-31 13F REGENERON PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-14 2018-12-31 13F REGENERON PHARMACEUTICALS COM Call 500 -85.71 1 -99.09 n/a n/a n/a
2018-11-14 2018-09-30 13F REGENERON PHARMACEUTICALS COM Call 3,500 600.00 110 478.95 n/a n/a n/a
2018-08-10 2018-06-30 13F REGENERON PHARMACEUTICALS COM Call 500 19 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.